Consequently, treatments that block the HMGB1-TLR2/4-MAPK immunosuppressive pathway and TIM-1+ Bregs may be a unique approach to treating HCC (Ye et al., 2018). Here, HMGB1 is linked to hepatocellular carcinoma.